Patents by Inventor Alan Ezrin
Alan Ezrin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080063707Abstract: Controlled release tablet formulations comprising a therapeutically effective amount of an ion channel modulating compound, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients suitable for controlled release formulations are disclosed.Type: ApplicationFiled: August 1, 2007Publication date: March 13, 2008Applicant: CARDIOME PHARMA CORP.Inventors: Gregory Beatch, Alan Ezrin
-
Publication number: 20080021005Abstract: This invention is directed to PEGlyated derivatives, drug conjugates and isotopic derivatives of certain ion channel modulating compounds.Type: ApplicationFiled: March 31, 2005Publication date: January 24, 2008Applicant: Cardiome Pharma Corp.Inventors: Elizabeth Cheu, Lewis Choi, Doug Chou, Allen Davidoff, Alan Ezrin, Grace Jung, Bertrand Plouvier, Aregahegn Yifru
-
Publication number: 20060199848Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, arrythmias (e.g. atrial fibrillation, atrial flutter, early afterdepolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.Type: ApplicationFiled: August 9, 2004Publication date: September 7, 2006Applicant: Cardiome Pharma Corp.Inventors: David Fedida, Gregory Beatch, Alan Ezrin, Peter Orth
-
Publication number: 20060135426Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: ApplicationFiled: December 14, 2005Publication date: June 22, 2006Applicant: CONJUCHEM, INC.Inventors: Dominique Bridon, Benoit L' Archeveque, Alan Ezrin, Darren Holmes, Anouk Leblanc, Serge St. Pierre
-
Publication number: 20060135536Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, early afterdepolarizations and prolongation of QT interval may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.Type: ApplicationFiled: August 9, 2004Publication date: June 22, 2006Applicant: Cardiome Pharma Corp.Inventors: David Fedida, Gregory Beatch, Alan Ezrin, Peter Orth, Christian Hesketh
-
Publication number: 20060058235Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: ApplicationFiled: August 30, 2005Publication date: March 16, 2006Applicant: CONJUCHEM, INC.Inventors: Dominique Bridon, Benoit L'Archeveque, Alan Ezrin, Darren Holmes, Anouk Leblanc, Serge St. Pierre
-
Publication number: 20060009377Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: ApplicationFiled: June 29, 2005Publication date: January 12, 2006Applicant: CONJUCHEM, INC.Inventors: Dominique Bridon, Benoit L'Archeveque, Alan Ezrin, Darren Holmes, Anouk Leblanc, Serge Pierre
-
Publication number: 20050187159Abstract: A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.Type: ApplicationFiled: February 25, 2005Publication date: August 25, 2005Applicant: ConjuChem, Inc.Inventors: Dominique Bridon, Alan Ezrin, Peter Milner, Darren Holmes, Karen Thibaudeau
-
Publication number: 20050119315Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, arrythmias (e.g. atrial fibrillation, atrial flutter, early afterdepolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.Type: ApplicationFiled: August 9, 2004Publication date: June 2, 2005Applicant: Cardiome Pharma Corp.Inventors: David Fedida, Gregory Beatch, Alan Ezrin, Peter Orth
-
Publication number: 20050070552Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, early afterdepolarizations and prolongation of QT interval may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.Type: ApplicationFiled: August 9, 2004Publication date: March 31, 2005Applicant: Cardiome Pharma Corp.Inventors: David Fedida, Gregory Beatch, Alan Ezrin, Peter Orth, Christian Hesketh
-
Publication number: 20050026993Abstract: Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds.Type: ApplicationFiled: May 3, 2004Publication date: February 3, 2005Inventors: Gregory Beatch, Alan Ezrin
-
Patent number: 6087375Abstract: Novel compounds comprising chemically reactive intermediates which can react with available reactive functionalities on blood components to form covalent linkages, where the resulting covalently-bound conjugates are found to have thrombin inhibition activity are provided. Specifically, the thrombin inhibitor compounds of the present invention are derivatives of the known thrombin inhibitor argatroban, which can be covalently linked to chemically reactive functionalities on various blood components. The conjugated thrombin inhibitors thereby have extended lifetimes in the bloodstream, as compared to the unconjugated parent drug, and are, therefore, capable of maintaining thrombin inhibitory activity for extended periods of time as compared to the unconjugated parent drug. Also provided herein are methods for inhibiting thrombin activity in vivo comprising administering to the bloodstream of a mammalian host the novel compounds of the present invention.Type: GrantFiled: June 11, 1999Date of Patent: July 11, 2000Assignee: ConjuChem, Inc.Inventors: Dominique P. Bridon, Alan Ezrin, Peter Milner